MRKR MARKER THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, MARKER THERAPEUTICS INC reported revenue of n/a, net income of −$1.83M and diluted EPS of −$0.09; for the fiscal year ended December 2025 revenue was $3.55M, down 46.2% on the year before.

MRKR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.55M, gross profit n/a, operating income −$12.9M, net income −$12.2M (margin -343.0%), EPS −$0.79
• Fiscal year ended Dec 2024: revenue $6.59M, gross profit n/a, operating income −$11.1M, net income −$10.7M (margin -162.8%), EPS −$1.19
• Fiscal year ended Dec 2023: revenue $3.31M, gross profit n/a, operating income −$14.6M, net income −$8.24M (margin -248.8%), EPS −$0.94
• Fiscal year ended Dec 2022: revenue $3.51M, gross profit n/a, operating income −$19.8M, net income −$29.9M (margin -851.9%), EPS −$3.58
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$39.5M, net income −$41.9M (margin n/a), EPS −$5.47

MRKR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$1.83M, EPS −$0.09
• Quarter ended Mar 31, 2026: revenue $752K (up 115.3% year over year), net income −$3.18M, EPS −$0.16
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.10M (down 51.0% year over year), net income −$1.70M, EPS $0.02
• Quarter ended Sep 30, 2025: revenue $1.23M (down 36.0% year over year), net income −$2.00M, EPS −$0.12
• Quarter ended Jun 30, 2025: revenue $861K (down 26.3% year over year), net income −$4.02M, EPS −$0.29
• Quarter ended Mar 31, 2025: revenue $349K (down 71.9% year over year), net income −$4.45M, EPS −$0.40
• Quarter ended Dec 31, 2024 (from the annual report): revenue $2.25M (up 113.1% year over year), net income −$3.84M, EPS −$0.41
• Quarter ended Sep 30, 2024: revenue $1.93M (up 647.7% year over year), net income −$2.31M, EPS −$0.26
• Quarter ended Jun 30, 2024: revenue $1.17M (up 53.3% year over year), net income −$2.19M, EPS −$0.25
• Quarter ended Mar 31, 2024: revenue $1.24M (up 0.8% year over year), net income −$2.39M, EPS −$0.27
• Quarter ended Dec 31, 2023 (from the annual report): revenue $1.06M (up 39.2% year over year), net income −$2.80M, EPS −$0.32
• Quarter ended Sep 30, 2023: revenue $258K (down 74.2% year over year), net income −$2.98M, EPS −$0.34
• Quarter ended Jun 30, 2023: revenue $763K (down 3.5% year over year), net income $2.52M, EPS $0.29
• Quarter ended Mar 31, 2023: revenue $1.23M (up 28.0% year over year), net income −$4.97M, EPS −$0.57
• Quarter ended Dec 31, 2022 (from the annual report): revenue $759K, net income −$3.86M, EPS −$0.45
• Quarter ended Sep 30, 2022: revenue $1000K, net income −$6.92M, EPS −$0.83
• Quarter ended Jun 30, 2022: revenue $791K, net income −$9.24M, EPS −$1.11
• Quarter ended Mar 31, 2022: revenue $964K, net income −$9.91M, EPS −$1.19
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.76M, EPS −$5.03
• Quarter ended Sep 30, 2021: revenue n/a, net income −$12.4M, EPS −$0.15

MRKR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$12.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$10.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$16.4M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$27.0M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$27.3M, share buybacks n/a

MRKR balance sheet

• Jun 30, 2026: cash $11.3M, total assets $14.6M, total liabilities $2.42M, shareholders' equity $12.2M
• Mar 31, 2026: cash $14.9M, total assets $17.4M, total liabilities $3.64M, shareholders' equity $13.8M
• Dec 31, 2025: cash $16.1M, total assets $19.1M, total liabilities $2.27M, shareholders' equity $16.8M
• Sep 30, 2025: cash $17.6M, total assets $21.7M, total liabilities $3.35M, shareholders' equity $18.4M
• Jun 30, 2025: cash $10.5M, total assets $14.8M, total liabilities $4.28M, shareholders' equity $10.5M
• Mar 31, 2025: cash $13.7M, total assets $17.0M, total liabilities $2.50M, shareholders' equity $14.5M
• Dec 31, 2024: cash $19.2M, total assets $22.0M, total liabilities $3.46M, shareholders' equity $18.6M
• Sep 30, 2024: cash $9.00M, total assets $10.9M, total liabilities $3.46M, shareholders' equity $7.45M

What is MRKR's revenue?

MARKER THERAPEUTICS INC reported $3.55M of revenue for the fiscal year ended December 2025.

Is MRKR profitable?

No. MARKER THERAPEUTICS INC lost $8.71M over the last four quarters.

What is MRKR's EPS?

Diluted earnings per share over the last four quarters were −$0.35; −$0.09 in the latest quarter.

MRKR ownership and insider trades · All stocks